Mycobacterium avium complex infection in HIV/AIDS patients

Expert Review of Anti-Infective Therapy

Volumn 6, Issue 3, 2008, Pages 351-363

  Corti, Marcelo ^a   Palmero, Domingo J ^a  

^a HOSPITAL F J MUÑIZ   (Argentina)

Author keywords

AIDS; Diagnosis; MAC; Mycobacterium avium complex; Mycobacterium avium intracellulare; Treatment

Indexed keywords

AMIKACIN; ANTIRETROVIRUS AGENT; AZITHROMYCIN; CLARITHROMYCIN; CLOFAZIMINE; ETHAMBUTOL; LINEZOLID; PLACEBO; PROTEINASE INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; ANTIINFECTIVE AGENT;

ABDOMINAL PAIN; ADJUVANT THERAPY; ANTIBIOTIC SENSITIVITY; BACTEREMIA; CLINICAL FEATURE; DIARRHEA; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; GENETIC PREDISPOSITION; HEPATOSPLENOMEGALY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MYCOBACTERIOSIS; MYCOBACTERIUM AVIUM; NEPHROTOXICITY; NEURITIS; NEUTROPENIA; OPTIC NEURITIS; OTOTOXICITY; PATHOGENESIS; RASH; REVIEW; UVEITIS; AIDS RELATED COMPLEX; ATYPICAL MYCOBACTERIOSIS; CLASSIFICATION; DRUG EFFECT; ISOLATION AND PURIFICATION; MICROBIOLOGY; MYCOBACTERIUM INTRACELLULARE AVIUM;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-BACTERIAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HUMANS; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION;

EID: 48449084474     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.6.3.351     Document Type: Review

References (103)

1. Griffith DE, Aksamit T, Brown-Elliott BA et al. An official ATS/ IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am. J. Resp. Crit. Care. Med. 175(4), 367-416 (2007).
2. Horsburgh CR, Selik RM. The epidemiology of disseminated nontuberculous mycobacterial infection in the acquired immunodeficiency syndrome (AIDS). Am. Rev. Respir. Dis. 139(1), 4-7 (1989).
3. Chaisson RE, Moore RD, Richman DD, Keruly J, Creagh T. Incidence and natural history of Mycobacterium avium complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. Am. Rev. Respir. Dis. 146(2), 285-289 (1992).
4. Shafer RW, Sierra MF. Mycobacterium xenopi, Mycobacterium fortuitum, Mycobacterium kansasii, and other nontuberculous mycobacteria in an area of endemicity for AIDS. Clin. Infect. Dis. 15(1), 161-162 (1992).
5. Kirschner, RA, Parker BC, Falkinham JO. Epidemiology of infection by nontuberculous mycobacteria. Mycobacterium avium, Mycobacterium intracellulare, and Mycobacterium scrofulaceum in acid, brown-water swamps of the southeastern United States and their association with environmental variables. Am. Rev. Respir. Dis. 145(2), 271-275 (1993).
6. Horsburgh CR Jr. Epidemiology of Mycobacterium avium complex. In: Mycobacterium avium complex infection: Progress in Research and Treatment. Korvick JA, Benson CA (Eds). Marcel Dekker, NY, USA 1-22 (1996).
7. Carter G, Wu M, Drummond DC, Bermudez LE. Characterization of biofilm formation by clinical isolates of Mycobacterium avium. J. Med. Microbiol. 52 (9), 747-752 (2003).
8. Primm TP, Lucero CA, Falkinham JO. Health impacts of environmental Mycobacteria. Clin. Microbiol. Rev. 106(17), 98-106 (2004).
9. Norton CD, Le Chevallier MW, Falkinham JO. Survival of Mycobacterium avium in a model distribution system. Water Res. 38(6), 1457-1466 (2004).
10. von Reyn CF, Maslow JN, Barber TW, Falkinham JO, Arbeit RD. Persistent colonization of potable water as a source of Mycobacterium avium infection in AIDS. Lancet 343(8906), 1137-1141 (1994).
11. Wolinsky, E. Mycobacterial lymphadenitis in children: a prospective study of 105 nontuberculous cases with long-term follow-up. Clin. Infect. Dis. 20(4), 954-963 (1995).
12. von Reyn CF, Waddell RD, Eaton T et al. Isolation of Mycobacterium avium complex from water in the United States, Finland, Zaire, and Kenya. J. Clin. Microbiol. 31 (12), 3227-3230 (1993).
13. George KL, Falkinham JO. Selective medium for the isolation and enumeration of Mycobacterium avium-intracellulare and M. scrofulaceum. Can. J. Microbiol. 32(1), 10-14 (1986).
14. Cirillo JD, Falkow S, Tompkins LS, Bermudez LE. Interaction of. Mycobacterium avium with environmental amoebae enhances virulence. Infect. Immun. 65(9), 3759-3467 (1997).
15. Kaur D, Berg S, Dinadayala P et al. Biosynthesis of mycobacterial lipoarabinomannan: role of a branching mannosyltransferase. Proc. Natl Acad. Sci. USA 103(37), 13664-13669 (2006).
16. Rastogi N, Goh KS, David HL. Enhancement of drug susceptibility of Mycobacterium avium by inhibitors of cell envelope synthesis. Antimicrob. Agents Chemother. 34(5), 759-764 (1990).
17. Hoffner SE, Svenson SB, Beezer AE. Microcalorimetric studies of the initial interaction between antimycobacterial drugs and Mycobacterium avium. J. Antimicrob. Chemother. 25(3), 353-359 (1990).
18. Tortoli E. Impact of genotypic studies on mycobacterial taxonomy: the new mycobacteria of the 1990's. Clin. Microbiol. Rev. 16 (2), 319-354 (2003).
19. Georgiev VS. Opportunistic Infections Treatment and Prophylaxis. Humana Press, NJ, USA 96 (2003).
20. Nightingale SD, Byrd LT, Southern PM, Jockusch JD, Cal SX, Wynne BA. Incidence of Mycobacterium avium-intracellulare complex bacteriemia in human immunodeficiency virus-positive patients. J. Infect. Dis. 165(6), 1082-1085 (1992).
21. Turenne CY, Semret M, Cousins DV, Collins DM, Behr MA. Sequencing of hsp65 distinguishes among subsets of the Mycobacterium avium complex. J. Clin. Microbiol. 44(2), 433-440 (2006).
22. Sangari FJ, Goodman J, Petrofsky M, Kolonoski P, Bermudez LE. Mycobacterium avium invades the intestinal mucosa primarily by interacting with enterocytes. Infect. Immun. 69, 1515-1520 (2001).
23. Chin DP, Hopewell P, Stone EN et al. Mycobacterium avium complex in the respiratory or gastrointestinal tract and the risk of Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection. J. Infect. Dis. 169(2), 289-295 (1994).
24. Champsi J, Young LS, Bermudez LE. Production of TNF-α, IL-6 and TGF-β, and expression of receptors for TNF-α and IL-6, during murine Mycobacterium avium infection. Immunology 84(4), 549-554 (1995).
25. McGregor RR, Hafner R, Wu JW et al. Clinical, microbiological, and immunological characteristics in HIV-infected subjects at risk for disseminated Mycobacterium avium complex disease: an AACTG study. AIDS Res. Hum. Retroviruses 21(8), 689-695 (2005).
26. Dorman SE, Holland SM. Interferon-γ and interleukin-12 pathway defects and human disease. Cytokine Growth Factor Rev. 11(4), 321 (2000)
27. Naik E, Le Blanc S, Tang J, Jacobson LP. Kaslow PA. The complexity of HLA class II (DRB1, DQB1, DM) associations with disseminated Mycobacterium avium complex infection among HIV-seropositive whites. J. Acquir. Immune Defic. Syndr. 33(2), 140-145 (2003).
28. Vázquez N, Greenwell-Wild T, Rekka S, Orenstein JM, Wahl SM. Mycobacterium avium-induced SOCS contributes to resistance to IFN-γ-mediated mycobactericidal activity in human macrophages. J. Leukoc. Biol. 80(5), 1136-1144 (2006).
29. Greenberg SS, Xie J, Kolls J, Mason C, Didier P. Rapid induction of mRNA for nitric oxide synthase II in rat alveolar macrophages by intratracheal administration of Mycobacterium tuberculosis and Mycobacterium avium. Proc. Soc. Exp. Biol. Med. 209(1), 46-53 (1995).
30. Mohgheghpour N, Gammon D, van Vollenhoven A, Hornig Y, Bermudez LE, Young LS. Mycobacterium avium reduces expression of costimulatory/ adhesion molecules by human monocytes. Cell. Immunol. 176(1), 82-91 (1997).
31. + lymphocytes are required for host protection against Mycobacterium avium infection and dissemination through the intestinal route. Infect. Immun. 7(5), 2621-2627 (2005).
32. Ghassemi M, Novak RM, Khalili MF, Zhou J. Viable Mycobacterium avium is required for the majority of human immunodeficiency virus-induced upregulation in monocytoid cells. J. Med. Microbiol. 52(10), 877-882 (2003)
33. Lazaro E, Coureau G, Guedj J et al. Change in T-lymphocyte count after initiation of highly active antiretroviral therapy in HIV-infected patients with history of Mycobacterium avium complex infection. Antivir. Ther. 11(3), 343-350 (2006).
34. + cell counts: a EuroSIDA study. J. Infect. Dis. 194(5), 633-641 (2006).
35. French M, Keane N, McKinnon E, Phung S, Price P. Susceptibility to OI in HIV-infected patients with increased CD4 T-cell counts on antiretroviral therapy may be predicted by markers of dysfunctional effector memory CD4 T cells and B cells. HIV Med. 8(3), 148-155 (2007).
36. Tomioka H. Adjunctive immunotherapy of mycobacterial infections. Curr. Pharm. Des. 10(26), 3297-3312 (2004).
37. Kedzierska K, Paukovics G, Handley A et al. Interferon-γ therapy activates human monocytes for enhanced phagocytosis of Mycobacterium avium complex in HIV-infected individuals. HIV Clin. Trials. 5(2), 80-85 (2004).
38. de Silva TI, Cope A, Goepel J, Greig JM. The use of adjuvant granulocyte-macrophage colony-stimulating factor in HIV-related disseminated atypical mycobacterial infection. J. Infect. 54(4), 207-210 (2007).
39. Jenkins PA, Campbell IA, Banks J, Gelder CM, Prescott RJ, Smith AP. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in the treatment of opportunist mycobacterial pulmonary diseases and an assessment of the value of immunotherapy with M. vaccae: a pragmatic, randomised trial by The British Thoracic Society. Thorax (2008) (Epub ahead of print).
40. Horsburgh CR Jr. The pathophysiology of disseminated Mycobacterium avium disease in AIDS. J. Infect. Dis. 179(Suppl. 3), S461-S465 (1999).
41. Barbaro DJ, Orcutt VL, Coldiron BM. Mycobacterium avium-Mycobacterium intracellulare infection limited to the skin and lymph nodes in patients with AIDS. Rev. Infect. Dis. 11(4), 625-628 (1989).
42. Benson CA. Disease due to the Mycobacterium avium complex in patients with AIDS: epidemiology and clinical syndrome. Clin. Infect. Dis. 18(Suppl.), 218-222 (1994).
43. Torriani FJ, McCutchan JA, Bozzette SA, Grafe MR, Havlir DV. Autopsy findings in AIDS patients with Mycobacterium avium complex bacteremia. J. Infect. Dis. 170(6), 1601-1605 (1994).
44. Inderlied CB, Kemper CA, Bermudez LE. The Mycobarterium avium complex. Clin. Microbiol. Rev. 6(3), 266-310 (1993).
45. Gordin FM, Cohn DL, Sullam PM, Schoenfelder JR, Wynne BA, Horsburgh CR Jr. Early manifestations of disseminated Mycobacterium avium complex disease: a prospective evaluation. J. Infect. Dis. 176(1), 126-132 (1997).
46. Benson CA, Ellner JJ. Mycobacterium avium complex infection and AIDS: advances in theory and practice. Clin. Infect. Dis. 17(1), 7-20 (1993).
47. Havlik JA Jr, Horsburgh CR Jr, Metchock B, Williams PP, Fann SA, Thompson SE 3rd. Disseminated Mycobacterium avium complex infection: clinical identification and epidemiologic trends. J. Inftct. Dis. 165(3), 577-580 (1992).
48. Karakousis PC, Moore RD, Chaisson RE. Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy. Lancet 4(9), 557-565 (2004).
49. Kuitert LM, Thomas MG, Ellis-Pegler RB. Outcome of untreated Mycobacterium avium-intracellulare complex infection in AIDS. AIDS 5(8), 1036-1038 (1991).
50. Modilevsky T, Sattler FR, Barnes PF. Mycobacterial disease in patients with human immunodeficiency virus infection. Arch. Intern. Med. 149(10), 2201-2205 (1989).
51. Helbert M, Robinson D, Buchanan D et al. Mycobacterial infection in patients infected with the human immunodeficiency virus. Thorax 45(11), 45-48 (1990).
52. Damsker B, Bottone EJ. Mycobacterium avium-Mycobacterium intracellulare from the intestinal tracts of patients with acquired immunodeficiency syndrome: concepts regarding acquisition and pathogenesis. J. Infect. Dis. 151(1), 179-181 (1985).
53. Gadkowski LB, Stout JE. Current challenges in diagnosing and treating nontuberculous mycobacterial pulmonary disease. Infect. Med. 23, 425-433 (2006).
54. Falkinharn III JO. Epidemiology of infection by nontuberculous mycobacteria. Clin. Microbiol. Rev. 9(2), 177-245 (1996).
55. Havlir D, Kemper CA, Deresinski S. Reproducibility of lysis-centrifugation cultures for quantification of Mycobacterium avium complex bacteremia. J. Clin. Microbiol. 31(7), 1794-1798 (1993).
56. Hellyer TJ, Brown IN, Taylor MB, Allen BW, Easmon CS. Gastrointestinal involvement in Mycobacterium avium-intracellulare infection of patients with HIV. J. Infect. 26(1), 55-66 (1993).
57. Pantongrag-Brown L, Krebs TL, Daly BD et al. Frequency of abdominal CT findings in AIDS patients with M. avium complex bacteraemia. Clin. Radiol. 53(11), 816-819 (1998).
58. Shanson DC, Dryden MS. Comparison of methods for isolating Mycobacterium avium intracellulare from blood of patients with AIDS. J. Clin. Pathol. 41(6), 687-690 (1988).
59. Hafner R, Inderlied CB, Peterson DM et al. Correlation of quantitative bone marrow and blood cultures in AIDS patients with disseminated Mycobacterium avium complex infection. J. Infect. Dis. 180(2), 438-447 (1999).
60. Kemper CA, Meng RC, Nussbaum J et al. Treatment of Mycobacterium avium complex bacteremia in AIDS with a four drug oral regimen. Rifampicin, ethambutol, clofazimine, and ciprofloxacin. Ann. Intern. Med. 116(4), 466-472 (1992).
61. Rolla V, Jacomet C, Salause B et al. Clinical and laboratory findings of disseminated Mycobacterium avium complex infection (dMAC) in a pair matched case-control study. Rev. Inst. Med. Trop. Sao Paulo 41(5), 273-277 (1999).
62. Patella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338(13), 853-860 (1998).
63. Corti M, Villafañe MF, Ambroggi M, Sawicki M, Gancedo E. Soft tissue abscess and lymphadenitis due to Mycobacterium avium complex as an expression of immune reconstitution inflammatory syndrome after a second scheme of highly active antiretroviral therapy. Rev. Inst. Med. Trop. Sao Paulo 49(4), 267-270 (2007).
64. Shelburne SA 3rd, Hamill RJ. The immune reconstitution inflammatory syndrome. AIDS Rev. 5(2), 67-79 (2003).
65. Phillips P, Kwiatkowski MB, Copland M, Craib K, Montaner J. Mycobacterial lymphadenitis associated with the initiation of combination antiretroviral therapy. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 20(2), 122-128 (1999).
66. Race EM, Adelson, Mitty J et al. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet 351(9098), 252-255 (1998).
67. Cabie A, Abet S, Brebion A, Desbois N, Sobesky G. Mycobacterial lymphadenitis after initiation of highly active antiretroviral therapy. Eur. J. Clin. Microbiol. Infect. Dis. 170(11), 812-813 (1998).
68. Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect. Dis. 5(6), 361-373 (2005).
69. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS 18(12), 1615-1627 (2004).
70. Kumarasamy N, Chaguturu S, Mayer KH et al. Incidence of immune reconstitution syndrome in HIV/tuberculosis co-infected patients after initiation of genetic antiretroviral therapy in India. J. Acquir. Immune Defic. Syndr. 37(5), 1574-1576 (2004).
71. Ridell J, Kaul DR, Karakousis PC, Gallant JE, Mitty J, Kazanjian PH. Mycobacterium avium complex immune reconstitution inflammatory syndrome: long term outcomes. J Transl. Med. 5(1), 50 (2007).
72. Reisner B, Gatson A, Woods G. Use of Gen-Probe AccuProbes to identify Mycobacterium avium complex, Mycobacterium tuberculosis complex, Mycobacterium kansasii, and Mycobacterium gordonae directly from BACTEC TB broth cultures. J. Clin. Microbiol. 32(12), 2995-2998 (1994).
73. Padilla E, Gonzalez V, Manterola J M et al. Comparative evaluation of the new version of the INNO-LiPA mycobacteria and genotype Mycobacterium assays for identification of Mycobacterium species from MB/BacT liquid cultures artificially inoculated with mycobacterial strains: J. Clin. Microbiol. 42(7), 3083-3088 (2004).
74. Gürtler V, Harforf C, Bywater J, Mayall BC. Direct identification of slowly growing Mycobacterium species by analysis of the intergenic 16S-23S rDNA spacer region (ISR) using a GelCompar II database containing sequence based optimization for restriction fragment site polymorphisms (RFLPs) for 12 enzymes. J. Microbiol. Methods 64(2), 185-199 (2006).
75. Hall L, Doerr KA, Wohlfiel SL, Roberts GD. Evaluation of the MicroSeq system for identification of mycobacteria by 16S ribosomal DNA sequencing and its integration into a routine clinical mycobacteriology laboratory. J. Clin. Microbiol. 41(4), 1447-1453 (2003).
76. Kilby JM, Marques MB, Jaye DL, Tabereaux PB, Reddy VB, Waites KB. The yield of bone marrow biopsy and culture compared with blood culture in the evaluation of HIV-infected patients for mycobacterial and fungal infections. Am. J. Med. 104(2), 123-128 (1998).
77. Pacios E, Alcalá L, Ruiz-Serrano MJ, de Viedma DJ et al. Evaluation of bone marrow and blood cultures for the recovery of mycobacteria in the diagnosis of disseminated mycobacterial infections, Clin. Microbiol. Infect. 10(8), 734-737 (2004).
78. Kobashi Y, Yoshida K, Miyashita N, Niki Y, Oka M. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates. J. Infect. Chemother. 12(4), 195-202 (2006).
79. National Committee for Clinical Laboratory Standards. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes. NCCLS document M24-A (ISBN 1-56238-500-3), PA, USA (2003).
80. Ntziora F, Falagas ME. Linezolid for the treatment of patients with mycobacterial infections a systematic review. Int. J. Tuberc. Lung Dis. 11(6), 606-611 (2007).
81. Meier A, Heifers L, Wallace RJ Jr et al. Molecular mechanisms of clarithromycin resistance in Mycobacterium avium: observation of multiple 23S rDNA mutations in clonal population. J. Infect. Dis. 174(2), 354-360 (1996).
82. Wallace RJ Jr, Brown BA, Griffith DE, Girard WM, Murphy DT. Clarithromycin regimens for pulmonary Mycobacterium avium complex: the first 50 patients. Am. J. Respir. Crit. Care. Med. 153(6), 1766-1772 (1996).
83. Griffith DE, Brown BA, Girard WM, Murphy DT, Wallace RJ Jr. Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus. Clin. Infect. Dis. 23(5), 983-989 (1996).
84. Chaisson RE, Benson CA, Dube MP et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease: a randomized, double-blind, dose-ranging study in patients with AIDS. Ann. Intern. Med. 121(12), 905-911 (1994).
85. Cohn DL, Fisher EJ, Peng GT et al. A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: excess mortality associated with high-dose clarithromycin. Clin. Infect. Dis. 29(1), 125-133 (1999).
86. Ward TT, Rimland D, Kauffman C, Huycke M, Evans TG, Heifets L. Randomized, open-label trial of azithromycin plus ethambutol vs. clarithromycin plus ethambutol as therapy for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection. Clin. Infect. Dis. 27(5), 1278-1285 (1998).
87. Benson CA, Kaplan JE, Masur H et al. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR Morb. Mortal. Wkly Rep. 53(RR15), 1-112 (2004).
88. Kuper JJ, D'Aprile M. Drug-drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin. Pharmacokinet. 39(3), 203-214 (2000).
89. Gordin FM, Sullam PM, Shafran SD et al. A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex. Clin. Infect. Dis. 28(5), 1080-1085 (1998).
90. Benson CA, Williams PL, Currier JS et al. A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome. Clin. Infect. Dis. 37(9), 1234-1243 (2003).
91. Chaisson RE, Keiser P, Pierce M et al. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection. AIDS 11(3), 311-317 (1997).
92. Fournier S, Burguière AM, Flahault A, Vincent V, Treilhou MP, Eliaszewicz M. Effect of adding dofazimine to combined clarithromycin-ethambutol therapy for Mycobacterium avium complex septicemia in AIDS patients. Eur. J. Clin. Microbiol. Infect. Dis. 18(1), 16-22 (1999).
93. Corti M, Palmero D. Antiretroviral treatment in patients with AIDS and mycobacterial diseases. Medicina (Buenos Aires) 65(4), 353-360 (2005).
94. Einarson A, Phillips E, Mawji F et al. A prospective controlled multicentre study of clarithromycin in pregnancy. Am. J. Perinatol. 15(9), 523-525 (1998).
95. Bermudez LE, Yamazaki Y. Effects of macrolides and ketolides on mycobacterial infections. Curr. Pharm. Des. 10(26), 3221-3228 (2004).
96. Kedzierska K, Paukovics G, Handley A et al. Interferon-γ therapy activates human monocytes for enhanced phagocytosis of Mycobacterium avium complex in HIV-infected individuals. HIV Clin. Trials 5(2), 80-85 (2004).
97. US Public Health Service, Infectious Diseases Society of America, Prevention of Opportunistic Infections Working Group. 2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Inftct. Dis. Obstet. Gynecol. 10(1), 3-64 (2002).
98. Havlir DV, Dube MP, Sattler FR et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azitkromycin, day rifabutin, or both. California Collaborative Treatment Group. N. Engl. J. Med. 335(6), 392-398 (2006).
99. Pierce M, Crampton S, Henry D et al. A randomized trial of darithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N. Engl. J. Med. 335(6), 384-391 (1996).
100. Kirk O, Reiss P, Ubberti-Foppa C et al. Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretraviral therapy. Ann. Intern. Med. 137(4), 239-250 (2002).
101. Lange CG, Woolley IJ, Brodt RH. Disseminated Mycobacterium avium-intracellulare complex (MAC) infection in the era of effective antiretroviral therapy: is prophylaxis still indicated? Drugs 64(7), 679-692 (2004).
102. Brooks JT, Song R, Hanson DL, Wolfe M, Swerdlow DL; Adult and Adolescent Spectrum of Disease Working Group. Discontinuation of primary prophylaxis against Mycobacterium avium complex infection in HIV-infected persons receiving antiretroviral therapy: observations from a large national cohort in the United States, 1992-2002. Clin. Infect. Dis. 41(4), 549-553 (2005).
103. Brooks JT, Song R, Hanson DL, Wolfe M, Swerdlow DL. Discontinuation of primary prophylaxis against Mycobacterium avium complex infection in HIV-infected persons receiving antiretroviral therapy: observations from a large national cohort in the United States, 1992-2002. Clin. Infect. Dis. 41(4), 549-553 (2005).